CDTRP 2026 Research Innovation Grant Competition Results

CDTRP is thrilled to announce the results of the CDTRP 2026 Research Innovation Grant Competition, made possible through our partnership with various esteemed organizations. We are proud to showcase all of the exciting projects that have been funded in this year’s competition.

We would like to extend our warmest congratulations to Dr. Karen Sherwood and Dr. Tom Blydt-Hansen and their team for being awarded the CDTRP KFOC Research Innovation Grant. We wish them all the best as they embark on their innovative project!

“The Kidney Foundation of Canada is excited to support this work which could see immunosuppression after transplantation as a thing of the past. While transplantation can provide a new outlook on life for many kidney patients, it is often accompanied by a lifelong complications resultant from the requirement to take medications to suppress the host immune system. Innovation that could contribute to the reduction of immunosuppressive medications, have the potential to result in meaningful change for the post transplant community, and increase the potential for transplant as a treatment in a larger percentage of the population.”

CDTRP KFOC Research Innovation Grant : Dr. Karen Sherwood and Dr. Tom Blydt-Hansen

Project Title: Precision Immune Genomics in Pediatric Kidney Transplantation: A Novel Application of Nanopore Adaptive Sampling for integrated genomic Risk Stratification

Main affiliation: University of British Columbia

Theme: 4 – Tailor an Optimal Immune System for Each Patient

Lay Abstract

Kidney transplantation gives children with kidney failure the opportunity for a longer, healthier life, but every child’s immune system is different. Some children develop early rejection or persistent inflammation that damages their transplanted kidney, while others thrive on standard treatment. Today, we lack the tools to predict before transplant which children carry an inherently higher immune risk, leaving clinicians unable to tailor immunosuppression to the individual child.

Answering this challenge sits at the heart of CDTRP’s vision: to tailor an optimal immune system for each patient. This study will examine 42 variations across 28 immune-related genes in DNA samples from 200 pediatric kidney transplant recipients in British Columbia. Each gene variant has been individually linked to rejection or graft failure in other studies; however, we propose to understand how they interact in aggregate to shape each child’s net immune response after transplantation.

Using Oxford Nanopore adaptive sampling, a novel sequencing strategy, we will build individual genetic risk profiles and connect them to real clinical outcomes: kidney biopsies, urine inflammatory markers, and long-term graft survival. Machine learning will identify which combinations of variants best predict early rejection, allograft inflammation, and graft failure.

The result will be a personalized pre-transplant immune risk score to guide donor selection, monitoring intensity, and immunosuppression dosing for each child. Patient, family, and donor partners are embedded throughout this work, co-developing how findings are interpreted and communicated, and ensuring that this genetic risk tool is meaningful, trustworthy, and ready for real-world clinical implementation. This precision approach directly supports the CDTRP mission of moving transplant medicine from reactive to proactive, individualized care.